BETHLEHEM, Pa., July 20, 2023 (GLOBE NEWSWIRE) -- OraSure Technologies, Inc. (NASDAQ: OSUR) has scheduled its regular earnings conference call covering 2023 second quarter financial results and certain business developments for 5:00 pm ET on Thursday, August 3, 2023.
A webcast of the conference call will be available on the investor relations page of OraSure’s website at https://orasure.gcs-web.com/events-and-presentations. Please click on the webcast link and follow the prompts for registration and access at least 10 minutes prior to the call. The webcast will be archived on OraSure’s website shortly after the call has ended and will be available for approximately 90 days.
To participate in the live conference call, please follow the link below to pre-register. After registering, you will be provided with your access details via email.
https://register.vevent.com/register/BIa2ec244bbd894460808bcc1818c5136e
| Investor Contact: Jason Plagman VP, Investor Relations This email address is being protected from spambots. You need JavaScript enabled to view it. | Media Contact: Amy Koch Director, Corporate Communications This email address is being protected from spambots. You need JavaScript enabled to view it. |
| Last Trade: | US$3.34 |
| Daily Change: | -0.14 -4.02 |
| Daily Volume: | 894,191 |
| Market Cap: | US$244.290M |
February 25, 2025 | |
C4 Therapeutics is pioneering a new class of small-molecule drugs that selectively destroy disease-causing proteins via degradation using the innate machinery of the cell. This targeted protein degradation approach offers advantages over traditional drugs, including the potential to treat a wider range of diseases...
CLICK TO LEARN MORE
Terns Pharmaceuticals is a clinical-stage biopharmaceutical company developing a portfolio of small-molecule product candidates to address serious diseases, including oncology and obesity. Terns’ pipeline contains three clinical stage development programs including GLP-1 receptor...
CLICK TO LEARN MORE
